Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints –– Patient reported efficacy outcomes ...

Alongside a new lab, MI:RNA has appointed Judy Keator as head of global business development. She has more than 22 years’ ...